Mi Lab Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 31-07-2024
- Paid Up Capital ₹ 0.70 M
as on 31-07-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.50 Cr
as on 31-07-2024
- Revenue 18.44%
(FY 2023)
- Profit 105.81%
(FY 2023)
- Ebitda 1239.89%
(FY 2023)
- Net Worth 0.27%
(FY 2023)
- Total Assets 4.74%
(FY 2023)
About Mi Lab Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.70 M.
The company currently has active open charges totaling ₹1.50 Cr.
Shanmugam Thirumalai, Lakshmanaperumal Thirumalai, and Lakshmanaperumal Nithya serve as directors at the Company.
- CIN/LLPIN
U74900KA2016PTC086646
- Company No.
086646
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Mar 2016
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bengaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Mi Lab Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shanmugam Thirumalai  | Director | 04-Mar-2016 | Current |
| Lakshmanaperumal Thirumalai | Director | 04-Mar-2016 | Current |
| Lakshmanaperumal Nithya | Director | 04-Mar-2016 | Current |
Financial Performance of Mi Lab Lifesciences.
Mi Lab Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.44% increase. The company also saw a substantial improvement in profitability, with a 105.81% increase in profit. The company's net worth moved up by a moderate rise of 0.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mi Lab Lifesciences?
In 2023, Mi Lab Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Maven Ilab Private LimitedActive 14 years 29 daysShanmugam Thirumalai, Lakshmanaperumal Thirumalai and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 Jun 2018 | ₹1.50 Cr | Open |
How Many Employees Work at Mi Lab Lifesciences?
Mi Lab Lifesciences has a workforce of 4 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mi Lab Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mi Lab Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
